These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18367000)

  • 21. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia.
    Amor AJ; Pinyol M; Solà E; Catalan M; Cofán M; Herreras Z; Amigó N; Gilabert R; Sala-Vila A; Ros E; Ortega E
    J Clin Lipidol; 2017; 11(2):551-561.e7. PubMed ID: 28502513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α.
    Lucero D; Miksztowicz V; Macri V; López GH; Friedman S; Berg G; Zago V; Schreier L
    Clin Investig Arterioscler; 2015; 27(4):167-74. PubMed ID: 25796423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review.
    Bjornstad P; Eckel RH
    Curr Diab Rep; 2018 Oct; 18(12):127. PubMed ID: 30328521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion.
    Avramoglu RK; Qiu W; Adeli K
    Front Biosci; 2003 Jan; 8():d464-76. PubMed ID: 12456312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid and lipoprotein dysregulation in insulin resistant states.
    Avramoglu RK; Basciano H; Adeli K
    Clin Chim Acta; 2006 Jun; 368(1-2):1-19. PubMed ID: 16480697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dyslipidemia].
    Kihara S
    Nihon Rinsho; 2013 Feb; 71(2):275-9. PubMed ID: 23631206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance.
    Savage DB; Semple RK
    Curr Opin Lipidol; 2010 Aug; 21(4):329-36. PubMed ID: 20581678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease.
    Poulsen MK; Nellemann B; Stødkilde-Jørgensen H; Pedersen SB; Grønbæk H; Nielsen S
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1637-46. PubMed ID: 26829441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease.
    Poulsen MK; Nellemann B; Bibby BM; Stødkilde-Jørgensen H; Pedersen SB; Grønbaek H; Nielsen S
    Diabetes Obes Metab; 2018 Oct; 20(10):2504-2509. PubMed ID: 29885082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity.
    Chan DC; Watts GF; Gan S; Wong AT; Ooi EM; Barrett PH
    Arterioscler Thromb Vasc Biol; 2010 May; 30(5):1043-50. PubMed ID: 20150556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Atherogenic dyslipidemia and the metabolic syndrome: pathophysiological mechanisms].
    Zák A; Slabý A
    Cas Lek Cesk; 2008; 147(9):459-70. PubMed ID: 18988488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.
    Semple RK; Sleigh A; Murgatroyd PR; Adams CA; Bluck L; Jackson S; Vottero A; Kanabar D; Charlton-Menys V; Durrington P; Soos MA; Carpenter TA; Lomas DJ; Cochran EK; Gorden P; O'Rahilly S; Savage DB
    J Clin Invest; 2009 Feb; 119(2):315-22. PubMed ID: 19164855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
    Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal relationship between diet-induced steatosis and onset of insulin/leptin resistance in male Wistar rats.
    Zhang L; Song H; Ge Y; Ji G; Yao Z
    PLoS One; 2015; 10(2):e0117008. PubMed ID: 25658428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of GLP-1 based therapies on diabetic dyslipidemia.
    Patel VJ; Joharapurkar AA; Shah GB; Jain MR
    Curr Diabetes Rev; 2014; 10(4):238-50. PubMed ID: 24998439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.